Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Shigella Vaccine Development: Finding the Path of Least Resistance

Shigella Vaccine Development: Finding the Path of Least Resistance Shigellaspp. represent the second most common etiologic pathogen causing childhood diarrhea in developing countries. There are no licensed Shigellavaccines, and progress for such vaccines has been limited. In this issue of Clinical and Vaccine Immunology, Riddle and colleagues (M. S. Riddle, R. W. Kaminski, C. Di Paolo, C. K. Porter, R. L. Gutierrez, et al., Clin Vaccine Immunol 23:908–917, 2016, http://dx.doi.org/10.1128/CVI.00224-16) report results from a phase I study of a parenterally administered monovalent O-polysaccharide “bioconjugate” directed against Shigella flexneri2a. Ultimately, the goal is to develop a broad-spectrum Shigellavaccine to address this public health concern. A parenteral Shigellavaccine capable of eliciting protection in children of developing countries would be an important tool to reach this goal. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Vaccine Immunology American Society For Microbiology

Shigella Vaccine Development: Finding the Path of Least Resistance

Shigella Vaccine Development: Finding the Path of Least Resistance

Clinical and Vaccine Immunology , Volume 23 (12) – Dec 1, 2016

Abstract

Shigellaspp. represent the second most common etiologic pathogen causing childhood diarrhea in developing countries. There are no licensed Shigellavaccines, and progress for such vaccines has been limited. In this issue of Clinical and Vaccine Immunology, Riddle and colleagues (M. S. Riddle, R. W. Kaminski, C. Di Paolo, C. K. Porter, R. L. Gutierrez, et al., Clin Vaccine Immunol 23:908–917, 2016, http://dx.doi.org/10.1128/CVI.00224-16) report results from a phase I study of a parenterally administered monovalent O-polysaccharide “bioconjugate” directed against Shigella flexneri2a. Ultimately, the goal is to develop a broad-spectrum Shigellavaccine to address this public health concern. A parenteral Shigellavaccine capable of eliciting protection in children of developing countries would be an important tool to reach this goal.

Loading next page...
 
/lp/american-society-for-microbiology/shigella-vaccine-development-finding-the-path-of-least-resistance-AGOOxmL6P9

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Society For Microbiology
Copyright
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
ISSN
1556-6811
eISSN
1556-679X
DOI
10.1128/CVI.00444-16
pmid
27707764
Publisher site
See Article on Publisher Site

Abstract

Shigellaspp. represent the second most common etiologic pathogen causing childhood diarrhea in developing countries. There are no licensed Shigellavaccines, and progress for such vaccines has been limited. In this issue of Clinical and Vaccine Immunology, Riddle and colleagues (M. S. Riddle, R. W. Kaminski, C. Di Paolo, C. K. Porter, R. L. Gutierrez, et al., Clin Vaccine Immunol 23:908–917, 2016, http://dx.doi.org/10.1128/CVI.00224-16) report results from a phase I study of a parenterally administered monovalent O-polysaccharide “bioconjugate” directed against Shigella flexneri2a. Ultimately, the goal is to develop a broad-spectrum Shigellavaccine to address this public health concern. A parenteral Shigellavaccine capable of eliciting protection in children of developing countries would be an important tool to reach this goal.

Journal

Clinical and Vaccine ImmunologyAmerican Society For Microbiology

Published: Dec 1, 2016

There are no references for this article.